Trials / Completed
CompletedNCT00788684
Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers
A Phase 1 Study Evaluating the Safety of ABT-263 in Combination With Rituximab in Subjects With CD20-positive Lymphoid Malignancies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 29 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 1 study evaluating the safety of ABT-263 administered in combination with rituximab in participants with CD20-positive lymphoproliferative disorders. The extension portion of the study will allow active participants to continue to receive ABT-263 for up to 14 years after the last participant transitions with quarterly study evaluations.
Conditions
- CD20-Positive Lymphoid Malignancies
- Chronic Lymphoid Leukemia
- Hematological Malignancies
- Non-Hodgkin's Lymphoma
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | rituximab | IV infusion once weekly for four doses |
| DRUG | ABT-263 | ABT-263: oral solution or tablets, once daily dosing until disease progression |
Timeline
- Start date
- 2009-07-21
- Primary completion
- 2025-02-07
- Completion
- 2025-02-07
- First posted
- 2008-11-11
- Last updated
- 2025-02-20
Locations
6 sites across 2 countries: United States, Australia
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT00788684. Inclusion in this directory is not an endorsement.